Akademik Veri Yönetim Sistemi
11th ULPAS, Bursa, Türkiye, 4 - 05 Kasım 2022, ss.205-206
Engineering items using bio-inspired ideas is not a new concept. The enthusiasm in forming and commercializing
nature-inspired products, however, has only recently begun to pick up momentum as researchers start to understand
the technical constraints and the endlessly basic, yet perfect, answers that have existed in natural mechanisms for
billions of years. Since the beginning of the field several decades ago, current research inspired by biomimicry in
regenerative medicine and health research holds much promise to restore or promote both structurally and functionally
of damaged tissues and whole organs. Despite the fact that many strategies have been investigated to understand the
mechanism and describe the status of this rapidly developing technology, historically, tissue engineering primarily
have focused on providing relatively static scaffolding factors. On the other hands, increasing evidence suggests that
the natural, dynamic three-dimensional micro-environment is important for directing cellular behavior. As a result, in
order to better resemble the natural extracellular matrix (ECM), there has recently been a focus on making scaffolds
more biocomplexity by adding adhesion, degradation, and three-dimensional features.
There are many applications by inspiration of the nature in contrast to conventional techniques, which still have some
restrictions on efficiency and various therapeutic substances. On the other hand, ‘organ on a chip’, a multi-channel 3D
microfluidic in vitro cell-based devices, can be a very intriguing tool for researching medication delivery methods. On
the other hand, multi-channel 3D microfluidic in vitro cell based systems referred to as ‘organ on a chip’ potentially
represents a very interesting tool for studying not only drug development, and also tissue evolution, organ physiology
and disease etiology.
Biomimetics will unavoidably play an important role in biomedical and tissue engineering, regenerative medicine, and
drug delivery systems, according to recent various studies on the biological systems by simulating the body's vascular
perfusion, physicochemical microenvironments, tissue-tissue interactions, and multicellular architectures. Clinical
applications of these future end-products, their monitoring, data collection points and timings with regulatory
endorsement must be standardized, endorsed, and optimized for controllability and long-term usage. This requires
developing a consensus at least between engineers, pharmacists, biologists and medical doctors.